Yıl: 2010 Cilt: 21 Sayı: 3 Sayfa Aralığı: 212 - 217 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Efficacy of probiotics in Helicobacter pylori eradication therapy

Öz:
Amaç: Proton pompa inhibitörü, amoksisilin ve klaritromisin içerikli üçlü tedavi, Helikobakter pilori eradikasyonunda sıkça kullanılmakta olmasına rağmen önemli bir oranda hastada başarısızlıkla sonuçlanmaktadır. Bu çalışmada, antibiyotik tedavisine probiyotik eklenmesinin H. pilori eradikasyonu üzerine etkisini araştırmayı amaçladık. İkinci amacımız ise probiyotiklerin, eradikasyon tedavisinin yan etkilerini önlemedeki etkilerini incelemek idi. Yöntem: Histopatolojik olarak H. pilori pozitif saptanmış 76 hasta 2 gruba ayrıldı ve her bir kişiye rastgele olarak iki tedavi protokolünden birisi uygulandı; grup A: Pantoprazol 40 mg 2x1, amoksisilin 1 gr 2x1, klaritromisin 500 mg 2x1 ve probiyotik içerikli yoğurt 125 ml (Bifidobacterium DN-173 010-1010 cfu/gr) 1x1, kahvaltı öncesi, 14 gün, grup B: Pantoprazol 40 mg 2x1, amoksisilin 1 gr 2x1 ve klaritromisin 500 mg 2x,14 gün. Hastalardan tedavi boyunca karşılaştıkları yan etkileri bildirmeleri istendi. Tedavi bitiminden 4 hafta sonra H. pilori durumu 13C-üre nefes testi ile kontrol edildi. Bulgular: Group A'da ki 38 hastanın 25'inde (%66), group B'de ki 38 hastanın 20'sinde (%53) H. pilori eradikasyonu sağlanmıştır. Group A'da başarı oranı group B'den daha yüksek olmakla birlikte, bu fark istatistiksel olarak anlamlı bulunmamıştır (p=0.350). Klasik üçlü tedaviye probiyotik eklenmesi stomatit ve kabızlık sıklığında anlamlı şekilde azalmaya yol açmıştır (sırasıyla, p=0.037 ve p=0.046). Sonuç: Üçlü tedaviye probiyotik eklenmesi, verilen doz ve modelde H. pilori eradikasyonunu arttırmamış ancak stomatit ve kabızlık görülme sıklığını azaltmıştır.
Anahtar Kelime: Kombine tedavi uygulaması Helicobacter enfeksiyonları İleriye dönük çalışma Proton pompa inhibitörleri Probiyotikler Helicobacter pylori İlaç tedavisi, kombinasyon

Konular: Cerrahi

Probiyotiklerin Helikobakter pilori eradikasyon tedavisindeki etkinliği

Öz:
Background/aims: Triple therapy with a proton pump inhibitor, amoxicillin and clarithromycin in Helicobacter pylori eradication is widely accepted, but this combination fails in a considerable number of cases. Our aim was to evaluate whether probiotic-containing yogurt affects the success of eradication. The second aim was to investigate the efficacy of probiotics in the prevention of the side effects related to eradication therapy. Methods: A total of 76 histopathologically proven H. pylori-positive patients enrolled in this study were randomized into two groups. The following regimens were recommended: Group A: pantoprazole (40 mg, b.i.d.), amoxicillin (1000 mg b.i.d.), clarithromycin (500 mg b.i.d.), and 125 ml of probiotic-containing yogurt (Bifidobacterium DN-173 010-1010 cfu/g) before breakfast for 14 days; and Group B: pantoprazole (40 mg, b.i.d.), amoxicillin (1000 mg b.i.d.) and clarithromycin (500 mg b.i.d.) for 14 days. Subjects were asked to report any side effects of therapy during the treatment period. H. pylori status was rechecked four weeks after the completion of the eradication therapy by 13Curea breath test. Results: H. pylori eradication was achieved in 25 of the 38 patients in Group A (66%) and in 20 of the 38 patients (53%) in Group B. Although the success rate was higher in Group A than in Group B, the difference was not significant (p=0.350). The addition of probiotics to the triple therapy significantly lessened the frequency of stomatitis and constipation (p=0.037 and p=0.046, respectively). Conclusions: The addition of probiotic-containing yogurt to the triple therapy did not increase the H. pylori eradication rates for the evaluated dosage and model; however, it decreased the frequency of stomatitis and constipation.
Anahtar Kelime: Proton Pump Inhibitors Probiotics Helicobacter pylori Drug Therapy, Combination Combined Modality Therapy Helicobacter Infections Prospective Studies

Konular: Cerrahi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Go MF, Crowe SE. Virulence and pathogenicity of Helicobacter pylori. Gastroenterol Clin North Am 2000; 29: 64970.
  • 2. Eslick GD, Lim LL, Byles JE, et al. Association of Helicobacter pylori infection with gastric carcinoma: a metaanalysis. Am J Gastroenterol 1999; 94(9): 2373-9.
  • 3. Kearney DJ. Retreatment of Helicobacter pylori infection after initial treatment failure. Am J Gastroenterol 2001; 96: 1335-9.
  • 4. Suerbaum S, Michetti P. Medical progress: Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-86.
  • 5. Malfertheine P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81.
  • 6. Lessbros-Pantoflickova D, Corthesy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr 2007; 137: 812-8.
  • 7. Canducci F, Cremonini F, Armuzzi A, et al. Probiotics and Helicobacter pylori eradication. Dig Liver Dis 2002; 34: 81-3.
  • 8. Kim MN, Kim N, Lee SH, et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter 2008; 13: 261-8.
  • 9. Nista EC, Candelli M, Cremonini F, et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther 2004; 20: 1181-8.
  • 10. Cindoruk M, Erkan G, Karakan T, et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebocontrolled double-blind study. Helicobacter 2007; 12: 30916.
  • 11. Gumurdulu Y, Serin E, Ozer B, et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol 2004; 10: 668-71.
  • 12. Aydin A, Onder GF, Akarca US, et al. The efficacy of twoweek therapy with ranitidine bismuth citrate, amoxicillin and clarithromycin on Helicobacter pylori eradication in clarithromycin-resistant and -sensitive cases. Turk J Gastroenterol 2005; 16: 203-6.
  • 13. Baglan PH, Bozdayi G, Ozkan M, et al. Clarithromycin resistance prevalence and Icea gene status in Helicobacter pylori clinical isolates in Turkish patients with duodenal ulcer and functional dyspepsia. J Microbiol 2006; 44: 40916.
  • 14. Kearney DJ. Retreatment of H. pylori infection after initial treatment failure. Am J Gastroenterol 2001; 96: 1335-9.
  • 15. Pantoflickova D, Corthesy-Theulaz I, Dorta G, et al. Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis. Aliment Pharmacol Ther 2003; 18: 805-13.
  • 16. Wang KY, Li SN, Liu CS, et al. Effects of ingesting Lactobacillus and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am J Clin Nutr 2004; 80: 737-41.
  • 17. Gotteland M, Poliak L, Cruchet S, et al. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus in children colonised by Helicobacter pylori. Acta Paediatr 2005; 94: 1747-51.
  • 18. Wendakoon CN, Thomson ABR, Ozimek L. Lack of therapeutic effect of a specially designed yogurt for the eradication of Helicobacter pylori. Digestion 2002; 65: 16-20.
  • 19. Cats A, Kuipers EJ, Boschaert MA, et al. Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther 2003; 17: 429-35.
  • 20. Sheu BS, Wu JJ, Lo CY, et al. Impact of supplement with Lactobacillusand Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16: 1669-75.
  • 21. Armuzzi A, Cremonini F, Ojetti V, et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy: a pilot study. Digestion 2001; 63: 1-7.
  • 22. Felley C. Probiotics and Helicobacter pylori. Best Pract Res Clin Gastroenterol 2003; 17: 785-91.
  • 23. Fontham ETH, Ruiz B, Perez A, et al. Determinants of Helicobacter pylori infection and chronic gastritis. Am J Gastroenterol 1995; 90: 1094-101.
  • 24. Picard J, Fiaramonti J, Francois A, et al. Review article: Bifidobacteria as probiotic agents-physiological effects and clinical benefits. Aliment Pharmacol Ther 2005; 22: 495512.
  • 25. Lewis SJ, Freedman AR. Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998; 12: 80722.
  • 26. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapyrelated side-effects: a parallel group, triple blind, placebocontrolled study. Am J Gastroenterol 2002; 97: 2744-9.
  • 27. Canducci F, Armuzzi A, Cremonini F, et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000; 14: 1625-9.
  • 28. Huebner ES, Surawicz CM. Probiotics in the prevention and treatment of gastrointestinal infections. Gastroenterol Clin North Am 2006; 35: 355-65.
APA YASAR B, ABUT E, kayadibi h, TOROS A, sezikli m, AKKAN Z, keskin ö, KURDAŞ Ö (2010). Efficacy of probiotics in Helicobacter pylori eradication therapy. , 212 - 217.
Chicago YASAR BÜLENT,ABUT Evren,kayadibi huseyin,TOROS AHMET BURAK,sezikli mesut,AKKAN Züleyha,keskin özcan,KURDAŞ Övünç Oya Efficacy of probiotics in Helicobacter pylori eradication therapy. (2010): 212 - 217.
MLA YASAR BÜLENT,ABUT Evren,kayadibi huseyin,TOROS AHMET BURAK,sezikli mesut,AKKAN Züleyha,keskin özcan,KURDAŞ Övünç Oya Efficacy of probiotics in Helicobacter pylori eradication therapy. , 2010, ss.212 - 217.
AMA YASAR B,ABUT E,kayadibi h,TOROS A,sezikli m,AKKAN Z,keskin ö,KURDAŞ Ö Efficacy of probiotics in Helicobacter pylori eradication therapy. . 2010; 212 - 217.
Vancouver YASAR B,ABUT E,kayadibi h,TOROS A,sezikli m,AKKAN Z,keskin ö,KURDAŞ Ö Efficacy of probiotics in Helicobacter pylori eradication therapy. . 2010; 212 - 217.
IEEE YASAR B,ABUT E,kayadibi h,TOROS A,sezikli m,AKKAN Z,keskin ö,KURDAŞ Ö "Efficacy of probiotics in Helicobacter pylori eradication therapy." , ss.212 - 217, 2010.
ISNAD YASAR, BÜLENT vd. "Efficacy of probiotics in Helicobacter pylori eradication therapy". (2010), 212-217.
APA YASAR B, ABUT E, kayadibi h, TOROS A, sezikli m, AKKAN Z, keskin ö, KURDAŞ Ö (2010). Efficacy of probiotics in Helicobacter pylori eradication therapy. Turkish Journal of Gastroenterology, 21(3), 212 - 217.
Chicago YASAR BÜLENT,ABUT Evren,kayadibi huseyin,TOROS AHMET BURAK,sezikli mesut,AKKAN Züleyha,keskin özcan,KURDAŞ Övünç Oya Efficacy of probiotics in Helicobacter pylori eradication therapy. Turkish Journal of Gastroenterology 21, no.3 (2010): 212 - 217.
MLA YASAR BÜLENT,ABUT Evren,kayadibi huseyin,TOROS AHMET BURAK,sezikli mesut,AKKAN Züleyha,keskin özcan,KURDAŞ Övünç Oya Efficacy of probiotics in Helicobacter pylori eradication therapy. Turkish Journal of Gastroenterology, vol.21, no.3, 2010, ss.212 - 217.
AMA YASAR B,ABUT E,kayadibi h,TOROS A,sezikli m,AKKAN Z,keskin ö,KURDAŞ Ö Efficacy of probiotics in Helicobacter pylori eradication therapy. Turkish Journal of Gastroenterology. 2010; 21(3): 212 - 217.
Vancouver YASAR B,ABUT E,kayadibi h,TOROS A,sezikli m,AKKAN Z,keskin ö,KURDAŞ Ö Efficacy of probiotics in Helicobacter pylori eradication therapy. Turkish Journal of Gastroenterology. 2010; 21(3): 212 - 217.
IEEE YASAR B,ABUT E,kayadibi h,TOROS A,sezikli m,AKKAN Z,keskin ö,KURDAŞ Ö "Efficacy of probiotics in Helicobacter pylori eradication therapy." Turkish Journal of Gastroenterology, 21, ss.212 - 217, 2010.
ISNAD YASAR, BÜLENT vd. "Efficacy of probiotics in Helicobacter pylori eradication therapy". Turkish Journal of Gastroenterology 21/3 (2010), 212-217.